These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 18485270)

  • 1. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
    Montouchet C; Ruff L; Balu S
    J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial).
    Miller PS; Smith DG; Jones P
    Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of restricted reimbursement on the use of statins in Finland: a register-based study.
    Martikainen JE; Saastamoinen LK; Korhonen MJ; Enlund H; Helin-Salmivaara A
    Med Care; 2010 Sep; 48(9):761-6. PubMed ID: 20706164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M; O'donnell J; Olsson A
    Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of rosuvastatin 20 mg for the prevention of cardiovascular morbidity and mortality: a Swedish economic evaluation of the JUPITER trial.
    Ohsfeldt RL; Olsson AG; Jensen MM; Gandhi SK; Paulsson T
    J Med Econ; 2012; 15(1):125-33. PubMed ID: 22050473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal.
    Pinto CG; Carrageta MO; Miguel LS
    Value Health; 2008; 11(2):154-9. PubMed ID: 18380628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prescribing high-dose lipid-lowering therapy early to avoid subsequent cardiovascular events: is this a cost-effective strategy?
    Ara R; Pandor A; Stevens J; Rafia R; Ward SE; Rees A; Durrington PN; Reynolds TM; Wierzbicki AS; Stevenson M
    Eur J Prev Cardiol; 2012 Jun; 19(3):474-83. PubMed ID: 21460076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of high, moderate and low-dose statins in the prevention of vascular events in the Brazilian public health system.
    Ribeiro RA; Duncan BB; Ziegelmann PK; Stella SF; Vieira JL; Restelatto LM; Polanczyk CA
    Arq Bras Cardiol; 2015 Jan; 104(1):32-44. PubMed ID: 25409878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.
    Costa-Scharplatz M; Ramanathan K; Frial T; Beamer B; Gandhi S
    Clin Ther; 2008 Jul; 30(7):1345-57. PubMed ID: 18691996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
    Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
    Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin.
    Lindgren P; Graff J; Olsson AG; Pedersen TJ; Jönsson B;
    Eur Heart J; 2007 Jun; 28(12):1448-53. PubMed ID: 17371782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE; Feely J; Sigurdsson EL;
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cost-effectiveness of a new statin (rosuvastatin) in the UK NHS.
    Palmer SJ; Brady AJ; Ratcliffe AE
    Int J Clin Pract; 2003 Nov; 57(9):792-800. PubMed ID: 14686571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.